Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.43 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.39 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.37 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3013561 | 1.00 | TAS1R3 (0.43) | TAS1R3TAS1R1L3MBTL1GAARAB9A | |
| SCHEMBL3013566 | 1.00 | TAS1R3 (0.43) | TAS1R3TAS1R1L3MBTL1GAARAB9A | |
| SCHEMBL3007363 | 0.90 | GAA (0.45) | TAS1R3TAS1R1GAARAB9A | |
| SCHEMBL3007354 | 0.90 | GAA (0.45) | TAS1R3TAS1R1GAARAB9A | |
| SCHEMBL3007360 | 0.90 | GAA (0.45) | TAS1R3TAS1R1GAARAB9A | |
| SCHEMBL13245185 | 0.89 | TAS1R3 (0.43) | TAS1R3TAS1R1L3MBTL1GAARAB9A | |
| SCHEMBL13267187 | 0.88 | TAS1R3 (0.51) | TAS1R3TAS1R1L3MBTL1GAARAB9A | |
| SCHEMBL13245114 | 0.88 | — | — | |
| SCHEMBL13245296 | 0.88 | — | — | |
| SCHEMBL3017884 | 0.85 | KMT2A (0.46) | RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9617256-B2 | Antibacterial agents | ACHAOGEN, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-20170088549-A1 | ANTIBACTERIAL AGENTS | ACHAOGEN, INC. | 2017-03-30 | — | — | US | disclosed |
| EP-2170814-B1 | ANTIBACTERIAL AGENTS | ACHAOGEN INC (US) | 2016-08-17 | — | — | EP | disclosed |
| EP-2662353-A2 | Antibacterial agents | Achaogen, Inc. (US) | 2013-11-13 | — | — | EP | disclosed |
| US-20100190766-A1 | ANTIBACTERIAL AGENTS | ACHAOGEN, INC. (US) | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170088549-A1 | ANTIBACTERIAL AGENTS | MRPL21, SI, ABCB11 | TAS1R3 4086/4885TAS1R1 3410/4885L3MBTL1 2488/4885 |
| US-20100190766-A1 | ANTIBACTERIAL AGENTS | MRPL21, SI, ABCB11 | TAS1R3 4086/4885TAS1R1 3410/4885L3MBTL1 2488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.